Curated News
By: NewsRamp Editorial Staff
September 28, 2026
MIMS Group Accelerates Global Growth with AI-Enabled Clinical Platforms
TLDR
- MIMS launches MIMS Pulse and expands eMIMS Plus globally, gaining advantage in clinical decision support and medical marketing.
- MIMS Pulse integrates medicines data with flexible deployment, while eMIMS Plus scales across markets with new clinical modules.
- MIMS advances safer clinical workflows and better patient outcomes by delivering trusted medicines information to more healthcare professionals.
- MIMS, with six decades of medical data, transforms into AI-enabled platforms and expands into the US and UK markets.
Impact - Why it Matters
This news matters because it signals a significant shift in how trusted medical information is delivered to healthcare professionals worldwide. MIMS has been a cornerstone of drug information in Asia-Pacific since 1963, and its move to modernize clinical decision support with AI and scalable platforms could lead to safer, more efficient patient care. As healthcare systems globally face increasing pressure to adopt digital tools, MIMS’ expansion into new markets and its focus on intelligence-led services could help bridge the gap between data and clinical practice. For healthcare professionals, this means access to more integrated, user-friendly resources that support quality use of medicines. For the life sciences industry, it opens up new ways to engage with stakeholders and understand markets. Ultimately, this transformation could improve patient outcomes by empowering clinicians with better information at the point of care.
Summary
MIMS Group, a leading Asia-Pacific provider of medicines information, clinical decision support, medical communications and marketing services, is accelerating product innovation and international expansion under the leadership of Group CEO Sohil Goswami, who was appointed in January 2026. The company is transforming its six decades of trusted medical data and expertise into new technology platforms, customer applications and services. A key development is the launch of MIMS Pulse, a next-generation Clinical Decision Support platform that combines MIMS’ medicines data and clinical knowledge with modern technology, flexible deployment and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, the company is scaling eMIMS Plus, a platform that brings trusted medicines information into a modern digital experience designed to achieve quality use of medicine. First launched in Australia, eMIMS Plus is now available in India and Malaysia, with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent.
MIMS is also developing its global CDS offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments. The company’s Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organisations. MIMS continues to develop digital events, AI-enabled content capabilities and new customer engagement models, and is exploring more connected, intelligence-led services to help healthcare and life sciences organisations better understand their markets, engage healthcare professionals and make more informed decisions. This work represents an important step beyond MIMS’ traditional information and communications models, applying its content data and market reach to new technology-enabled services. As Goswami stated, “For decades, healthcare professionals have trusted MIMS’ medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services.” The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities and reach into new areas of healthcare. The news was distributed via Media OutReach Newswire.
Source Statement
This curated news summary relied on content distributed by Media Outreach. Read the original source here, MIMS Group Accelerates Global Growth with AI-Enabled Clinical Platforms
